Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:KYTX NASDAQ:RADX NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.26+2.0%$2.86$1.20▼$5.69$184.81M2.931.86 million shs149,724 shsKYTXKyverna Therapeutics$4.03+3.2%$3.72$1.78▼$7.35$174.28M3.08359,455 shs14,432 shsRADXRadiopharm Theranostics$7.24+7.3%$5.12$3.50▼$50.82$57.05MN/A92,254 shs24,831 shsSCLXScilex$24.52-4.6%$15.63$3.60▼$39.90$171.18M1.34133,119 shs78,323 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.85%+4.59%+15.58%+37.50%-48.47%KYTXKyverna Therapeutics-0.26%+0.26%+11.40%+32.09%-45.69%RADXRadiopharm Theranostics+3.85%+16.38%+38.04%+24.08%+674,999,900.00%SCLXScilex-2.21%+15.92%+42.15%+453.88%-36.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$3.26+2.0%$2.86$1.20▼$5.69$184.81M2.931.86 million shs149,724 shsKYTXKyverna Therapeutics$4.03+3.2%$3.72$1.78▼$7.35$174.28M3.08359,455 shs14,432 shsRADXRadiopharm Theranostics$7.24+7.3%$5.12$3.50▼$50.82$57.05MN/A92,254 shs24,831 shsSCLXScilex$24.52-4.6%$15.63$3.60▼$39.90$171.18M1.34133,119 shs78,323 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-1.85%+4.59%+15.58%+37.50%-48.47%KYTXKyverna Therapeutics-0.26%+0.26%+11.40%+32.09%-45.69%RADXRadiopharm Theranostics+3.85%+16.38%+38.04%+24.08%+674,999,900.00%SCLXScilex-2.21%+15.92%+42.15%+453.88%-36.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.14Buy$11.67265.73% UpsideKYTXKyverna Therapeutics 3.14Buy$16.60324.55% UpsideRADXRadiopharm Theranostics 3.67Strong Buy$15.00122.22% UpsideSCLXScilex 2.50Moderate Buy$455.001,670.43% UpsideCurrent Analyst Ratings BreakdownLatest RADX, BDTX, SCLX, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.009/3/2025BDTXBlack Diamond TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.008/29/2025KYTXKyverna TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $10.008/20/2025KYTXKyverna TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform8/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.007/21/2025RADXRadiopharm TheranosticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.007/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$11.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M2.59N/AN/A$1.47 per share2.17KYTXKyverna TherapeuticsN/AN/AN/AN/A$6.17 per shareN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/AN/ASCLXScilex$56.59M3.16N/AN/A($27.68) per share-0.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$69.68M$0.2313.87N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)KYTXKyverna Therapeutics-$127.48M-$3.68N/AN/AN/AN/A-64.98%-56.17%11/12/2025 (Estimated)RADXRadiopharm TheranosticsN/AN/A0.00∞N/AN/AN/AN/AN/ASCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)Latest RADX, BDTX, SCLX, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million8/12/2025Q2 2025KYTXKyverna Therapeutics-$1.00-$0.97+$0.03-$0.97N/AN/A8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.738.73KYTXKyverna TherapeuticsN/A5.395.39RADXRadiopharm TheranosticsN/AN/AN/ASCLXScilexN/A0.110.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%KYTXKyverna Therapeutics18.08%RADXRadiopharm TheranosticsN/ASCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%KYTXKyverna Therapeutics22.00%RADXRadiopharm TheranosticsN/ASCLXScilex7.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableKYTXKyverna Therapeutics9643.25 millionN/AOptionableRADXRadiopharm TheranosticsN/A7.88 millionN/AN/ASCLXScilex806.96 million6.40 millionOptionableRADX, BDTX, SCLX, and KYTX HeadlinesRecent News About These CompaniesState of Wyoming Has $33,000 Stock Position in Scilex Holding Company $SCLXSeptember 13 at 3:12 AM | marketbeat.comSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business CombinationSeptember 4, 2025 | globenewswire.comArmistice Capital LLC Has $3.43 Million Stake in Scilex Holding Company $SCLXSeptember 3, 2025 | marketbeat.comScilex (NASDAQ:SCLX) Trading Up 10.1% - Time to Buy?August 25, 2025 | marketbeat.comScilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered ...August 21, 2025 | theglobeandmail.comScilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details InsideAugust 21, 2025 | msn.comScilex Holding Company and Semnur Pharmaceuticals Announce $20 Million Private Placement for SP-102 Clinical Trial and Leadership TransitionAugust 21, 2025 | quiverquant.comQScilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex's CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to RegulatoAugust 21, 2025 | globenewswire.comScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral ...August 15, 2025 | theglobeandmail.comScilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of ScilexAugust 13, 2025 | globenewswire.comScilex Holding Co. (SCLX) Stock Price Today - WSJJuly 24, 2025 | wsj.comSCLX Scilex Holding Company - Seeking AlphaJuly 1, 2025 | seekingalpha.comScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...June 25, 2025 | theglobeandmail.comScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the BoardJune 23, 2025 | globenewswire.comScilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review JournalJune 5, 2025 | globenewswire.comScilex Holding Stock Price HistoryJune 1, 2025 | investing.comScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FLMay 16, 2025 | globenewswire.comScilex adjusts director compensation post-stock splitMay 13, 2025 | investing.comScilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.May 1, 2025 | globenewswire.comScilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price RuleApril 30, 2025 | globenewswire.comScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025April 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRADX, BDTX, SCLX, and KYTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$3.26 +0.07 (+2.04%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Kyverna Therapeutics NASDAQ:KYTX$4.03 +0.12 (+3.17%) As of 10:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Radiopharm Theranostics NASDAQ:RADX$7.24 +0.49 (+7.26%) As of 10:32 AM EasternRadiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.Scilex NASDAQ:SCLX$24.52 -1.18 (-4.58%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
